KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Neonatal BCG vaccination to prevent asthma: Results from the MIS BAIR randomized controlled trial.

Laure F Pittet, Emily K Forbes, Susan Donath, Kate L Francis, Kaya Gardiner, Katie L Flanagan, Anne-Louise Ponsonby, Roy Robins-Browne, Frank Shann, Mike South, Peter Vuillermin, Dan Casalaz, Nigel Curtis, Nicole L Messina, Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR) Group

Pediatr Allergy Immunol 36(6) e70110

PMID40464744
PMCIDPMC12136015
DOI10.1111/pai.70110
发表日期2025-06-04
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Asthma has a significant impact worldwide, but prevention strategies remain limited. We aimed to evaluate the efficacy of neonatal BCG vaccination in preventing asthma by modulating early-life immunity. METHODS: The Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR) was a phase 3 multicentre randomized controlled trial in Victoria, Australia. Infants were randomly assigned to receive the BCG-Denmark vaccine or no intervention within 10 days of birth. The incidence of asthma at 5 years of age was estimated using the International Study of Asthma and Allergies in Childhood questions. CLINICALTRIAL: gov (NCT01906853). RESULTS: A total of 1272 infants were randomized. The adjusted incidence of asthma was 14.4% in the BCG group compared to 16.0% in the control group (adjusted risk difference [aRD] -1.7 percentage points; 95%CI -7.4, 3.9). Secondary outcomes, including severe asthma and use of preventer medication, showed similar trends, with an aRD of -3.9 (95%CI -7.7, 0.0), and -5.6 (95%CI -10.9, -0.4), respectively, favoring the BCG group. Among participants with one or both parents asthmatic, the rate of asthma was also lower in the BCG group (17.6%) compared with the control group (24.7%; aRD -7.2; 95%CI -15.9, 1.5), although a test for interaction was not significant (p = .07). CONCLUSIONS: While the point estimates suggested BCG vaccination might protect against asthma, the wide uncertainty around the estimates means further studies with larger sample sizes are needed to evaluate the long-term benefits of BCG vaccination beyond its primary indication.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。